RSV lower respiratory tract disease
Vaccines · 2024–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| respiratory syncytial virus vaccine (RSVPreF3 OA) Prevention of RSV-confirmed lower respiratory tract disease (LRTD) in adults aged 60 years and above, including those with medical conditions associated with… | Mar 2026 | Recommended with restriction | input received Asthma Australia · Australasian Society of Clinical Immunology and Allergy · Australian Diabetes Society · Cystic Fibrosis Australia · Heart Support Australia · Immunisation Coalition · Immunisation Foundation · Kidney Health Australia · Lung Foundation Australia · Spleen Australia |
| nirsevimab Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and… | May 2025 | Deferred | 15 individuals Asthma Australia · Immunisation Foundation · Lung Foundation Australia · National Aboriginal Community Controlled Health Organisation · Other Respiratory Illnesses Community Reference Group |
| mRNA-1345 Prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals aged ≥75 years and Aboriginal and Torres Strait… | Nov 2025 | Deferred | input received Asthma Australia · Lung Foundation Australia |
| nirsevimab Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in neonates and infants born during or entering their first RSV season;… | Jul 2024 | Not recommended | 15 individuals Lung Foundation Australia · Asthma Australia · National Aboriginal Community Controlled Health Organisation · Immunisation Foundation · Australasian Society for Infectious Diseases · Other Respiratory Illnesses Community Reference Group |
| respiratory syncytial virus vaccine, recombinant pre-fusion F protein 3 older adult Prevention of respiratory syncytial virus (RSV)-confirmed lower respiratory tract disease in older adults. Two alternative populations were considered: adults… | Jul 2024 | Not recommended | 9 individuals Immunisation Foundation · Lung Foundation Australia · Asthma Australia · National Asthma Council Australia · National Aboriginal Community Controlled Health Organisation · Australasian Society of Clinical Immunology and Allergy |
Who spoke
Asthma Australia · Lung Foundation Australia · Immunisation Foundation · National Aboriginal Community Controlled Health Organisation · Australasian Society of Clinical Immunology and Allergy · Other Respiratory Illnesses Community Reference Group · Australian Diabetes Society · Cystic Fibrosis Australia · Heart Support Australia · Immunisation Coalition · Kidney Health Australia · Spleen Australia
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| clesrovimabENFLONSIA clesrovimab 105 mg in 0.7 mL solution for injection prefille | 2026 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.